UBS AM’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.06M | Sell |
557,170
-300,664
| -35% | -$4.31M | ﹤0.01% | 1321 |
|
|
2025
Q4 | $12.2M | Buy |
857,834
+34,903
| +4% | +$343K | ﹤0.01% | 1042 |
|
|
2025
Q3 | $6.48M | Sell |
822,931
-432,872
| -34% | -$3.08M | ﹤0.01% | 1243 |
|
|
2025
Q2 | $7.2M | Buy |
1,255,803
+183,329
| +17% | +$1.18M | ﹤0.01% | 1521 |
|
|
2025
Q1 | $8.75M | Buy |
1,072,474
+113,803
| +12% | +$1.05M | ﹤0.01% | 1287 |
|
|
2024
Q4 | $9.03M | Buy |
958,671
+471,902
| +97% | +$4.91M | ﹤0.01% | 1298 |
|
|
2024
Q3 | $5.2M | Sell |
486,769
-47,310
| -9% | -$515K | ﹤0.01% | 1548 |
|
|
2024
Q2 | $5.3M | Buy |
534,079
+282,846
| +113% | +$2.9M | ﹤0.01% | 1450 |
|
|
2024
Q1 | $2.96M | Sell |
251,233
-6,567
| -3% | -$84K | ﹤0.01% | 1489 |
|
|
2023
Q4 | $3.66M | Buy |
257,800
+11,761
| +5% | +$134K | ﹤0.01% | 1400 |
|
|
2023
Q3 | $2.99M | Sell |
246,039
-25,363
| -9% | -$327K | ﹤0.01% | 1434 |
|
|
2023
Q2 | $3.01M | Hold |
271,402
| – | – | ﹤0.01% | 1453 |
|
|
2023
Q1 | $3.01M | Buy |
271,402
+21,731
| +9% | +$268K | ﹤0.01% | 1453 |
|
|
2022
Q4 | $3.05M | Buy |
249,671
+28,777
| +13% | +$324K | ﹤0.01% | 1352 |
|
|
2022
Q3 | $2.31M | Sell |
220,894
-50,585
| -19% | -$564K | ﹤0.01% | 1528 |
|
|
2022
Q2 | $2.92M | Buy |
271,479
+2,453
| +0.9% | +$20.2K | ﹤0.01% | 1449 |
|
|
2022
Q1 | $2.55M | Sell |
269,026
-10,461
| -4% | -$98.1K | ﹤0.01% | 1672 |
|
|
2021
Q4 | $3.23M | Sell |
279,487
-6,154
| -2% | -$68.6K | ﹤0.01% | 1626 |
|
|
2021
Q3 | $2.73M | Sell |
285,641
-39,196
| -12% | -$401K | ﹤0.01% | 1692 |
|
|
2021
Q2 | $3.13M | Buy |
324,837
+10,288
| +3% | +$100K | ﹤0.01% | 1637 |
|
|
2021
Q1 | $3.11M | Buy |
314,549
+26,457
| +9% | +$410K | ﹤0.01% | 1562 |
|
|
2020
Q4 | $6.65M | Sell |
288,092
-1,217,486
| -81% | -$24.9M | ﹤0.01% | 1185 |
|
|
2020
Q3 | $21.3M | Buy |
1,505,578
+1,215,044
| +418% | +$17.7M | 0.01% | 746 |
|
|
2020
Q2 | $4.38M | Sell |
290,534
-4,061
| -1% | -$49.5K | ﹤0.01% | 1169 |
|
|
2020
Q1 | $2.72M | Buy |
294,595
+18,286
| +7% | +$174K | ﹤0.01% | 1290 |
|
|
2019
Q4 | $2.69M | Buy |
276,309
+28,188
| +11% | +$258K | ﹤0.01% | 1467 |
|
|
2019
Q3 | $1.99M | Buy |
248,121
+40,135
| +19% | +$436K | ﹤0.01% | 1614 |
|
|
2019
Q2 | $2.6M | Buy |
207,986
+50,218
| +32% | +$637K | ﹤0.01% | 1460 |
|
|
2019
Q1 | $2.15M | Buy |
157,768
+20,446
| +15% | +$250K | ﹤0.01% | 1483 |
|
|
2018
Q4 | $1.32M | Buy |
137,322
+19,811
| +17% | +$218K | ﹤0.01% | 1621 |
|
|
2018
Q3 | $1.42M | Sell |
117,511
-1,334
| -1% | -$18.7K | ﹤0.01% | 1651 |
|
|
2018
Q2 | $1.86M | Sell |
118,845
-5,117
| -4% | -$77.4K | ﹤0.01% | 1537 |
|
|
2018
Q1 | $1.86M | Buy |
123,962
+19,017
| +18% | +$289K | ﹤0.01% | 1495 |
|
|
2017
Q4 | $1.51M | Buy |
104,945
+40,793
| +64% | +$560K | ﹤0.01% | 1560 |
|
|
2017
Q3 | $967K | Buy |
64,152
+13,396
| +26% | +$177K | ﹤0.01% | 1728 |
|
|
2017
Q2 | $511K | Buy |
50,756
+82
| +0.2% | +$660 | ﹤0.01% | 1877 |
|
|
2017
Q1 | $361K | Buy |
50,674
+21,174
| +72% | +$134K | ﹤0.01% | 1954 |
|
|
2016
Q4 | $147K | Sell |
29,500
-15,500
| -34% | -$107K | ﹤0.01% | 2198 |
|
|
2016
Q3 | $333K | Hold |
45,000
| – | – | ﹤0.01% | 2207 |
|
|
2016
Q2 | $246K | Sell |
45,000
-550,060
| -92% | -$3.85M | ﹤0.01% | 2323 |
|
|
2016
Q1 | $5.03M | Sell |
595,060
-361,125
| -38% | -$2.56M | 0.01% | 1021 |
|
|
2015
Q4 | $9.28M | Buy |
956,185
+5,700
| +0.6% | +$51.4K | 0.01% | 885 |
|
|
2015
Q3 | $13.3M | Sell |
950,485
-81,415
| -8% | -$1.28M | 0.01% | 797 |
|
|
2015
Q2 | $14.6M | Buy |
1,031,900
+21,900
| +2% | +$263K | 0.01% | 795 |
|
|
2015
Q1 | $11M | Buy |
1,010,000
+17,600
| +2% | +$155K | 0.01% | 857 |
|
|
2014
Q4 | $8.26M | Buy |
992,400
+6,400
| +0.6% | +$43.9K | 0.01% | 925 |
|
|
2014
Q3 | $5.87M | Sell |
986,000
-386,700
| -28% | -$2.03M | 0.01% | 997 |
|
|
2014
Q2 | $4.58M | Sell |
1,372,700
-1,082,700
| -44% | -$2.54M | ﹤0.01% | 1052 |
|
|
2014
Q1 | $5.08M | Hold |
2,455,400
| – | – | 0.01% | 1035 |
|
|
2013
Q4 | $5.77M | Hold |
2,455,400
| – | – | 0.01% | 977 |
|
|
2013
Q3 | $5.7M | Buy |
2,455,400
+1,211,200
| +97% | +$3.04M | 0.01% | 946 |
|
|
2013
Q2 | $2.9M | Buy |
+1,244,200
| New | +$3.82M | ﹤0.01% | 1094 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
UBS AM's FOLD Position: Q1 2026 in Review
UBS AM reduced its Amicus Therapeutics (FOLD) stake by 35% in Q1 2026, selling an estimated $4.31M and leaving 557,170 shares worth $8.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1321.
UBS AM first reported a position in FOLD in Q2 2013 and has held it in 52 quarters since. The position peaked at $21.3M in Q3 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- UBS AM held 557,170 shares of Amicus Therapeutics worth $8.06M as of Q1 2026.
- UBS AM sold 300,664 Amicus Therapeutics shares in Q1 2026, an estimated $4.31M.
- Amicus Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #1321 holding.
- UBS AM first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 52 quarters since.
- UBS AM's Amicus Therapeutics position peaked at $21.3M in Q3 2020.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.